Abstract
Background:
Menkes disease (MD) is a disorder of copper transport caused by ATP7A mutations. Although parenteral copper supplements are partly effective in treating MD, the copper level in the brain remains insufficient, whereas copper accumulates in the kidney. We investigated the copper-trafficking efficacy of copper-pyruvaldehyde bis(N4-methylthiosemicarbazone) (Cu-PTSM), a lipophilic copper complex, in macular mice, an animal model of MD.
Methods:
Macular mice were treated with cupric chloride (CuCl2) or Cu-PTSM on postnatal days 4, 10, and 17. At 4 wk of age, the copper levels in major organs and cytochrome oxidase (CO) activity in brain tissue were measured. Hematology, blood biochemistry, and urinary β2-microglobulin (β2-M) secretion were also assessed.
Results:
The copper levels in the brains of the Cu-PTSM-treated group remained low, but CO activity in the cerebral and cerebellar cortices in the Cu-PTSM-treated group were higher than those in the CuCl2-treated group. There were no significant differences in hematological or biochemical findings or in urinary β2-M secretion among the groups.
Conclusion:
Although the copper-trafficking efficacy of Cu-PTSM was limited, the improved CO activity in the brain suggests that Cu-PTSM delivered copper more effectively to neuronal CO than did CuCl2. Reduced renal copper accumulation may be beneficial in prolonged copper supplementation.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Kodama H, Murata Y . Molecular genetics and pathophysiology of Menkes disease. Pediatr Int 1999;41:430–5.
Lutsenko S, Barnes NL, Bartee MY, Dmitriev OY . Function and regulation of human copper-transporting ATPases. Physiol Rev 2007;87:1011–46.
Kodama H, Fujisawa C . Copper metabolism and inherited copper transport disorders: molecular mechanisms, screening and treatment. Metallomics 2009;1:42–52.
Sherwood G, Sarkar B, Kortsak AS . Copper histidinate therapy in Menkes’ disease: prevention of progressive neurodegeneration. J Inherit Metab Dis 1989;12:Suppl 2:393–6.
Sarkar B, Lingertat-Walsh K, Clarke JT . Copper-histidine therapy for Menkes disease. J Pediatr 1993;123:828–30.
Kodama H, Sato E, Gu YH, Shiga K, Fujisawa C, Kozuma T . Effect of copper and diethyldithiocarbamate combination therapy on the macular mouse, an animal model of Menkes disease. J Inherit Metab Dis 2005;28:971–8.
Tanaka K, Kobayashi K, Fujita Y, Fukuhara C, Onosaka S, Min K . Effects of chelators on copper therapy of macular mouse, a model animal of Menkes’ kinky disease. Res Commun Chem Pathol Pharmacol 1990;69:217–27.
Green MA, Klippenstein DL, Tennison JR . Copper(II) bis(thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET. J Nucl Med 1988;29:1549–57.
Green MA, Mathias CJ, Welch MJ,et al. Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. J Nucl Med 1990;31:1989–96.
Baerga ID, Maickel RP, Green MA . Subcellular distribution of tissue radiocopper following intravenous administration of 67Cu-labeled Cu-PTSM. Int J Rad Appl Instrum B 1992;19:697–701.
Fujibayashi Y, Wada K, Taniuchi H, Yonekura Y, Konishi J, Yokoyama A . Mitochondria-selective reduction of 62Cu-pyruvaldehyde bis(N4-methylthiosemicarbazone) (62Cu-PTSM) in the murine brain; a novel radiopharmaceutical for brain positron emission tomography (PET) imaging. Biol Pharm Bull 1993;16:146–9.
Mercer JF . Menkes syndrome and animal models. Am J Clin Nutr 1998;67(5 Suppl):1022S–8S.
Yamano T, Shimada M, Kawasaki H, Onaga A, Nishimura M . Clinico-pathological study on macular mutant mouse. Acta Neuropathol 1987;72:256–60.
Mori M, Nishimura M . A serine-to-proline mutation in the copper-transporting P-type ATPase gene of the macular mouse. Mamm Genome 1997;8:407–10.
Murata Y, Kodama H, Abe T,et al. Mutation analysis and expression of the mottled gene in the macular mouse model of Menkes disease. Pediatr Res 1997;42:436–42.
Blower PJ, Lewis JS, Zweit J . Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996;23:957–80.
Dearling JL, Lewis JS, Mullen GE, Rae MT, Zweit J, Blower PJ . Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 1998;25:788–92.
Taniuchi H, Fujibayashi Y, Okazawa H, Yonekura Y, Konishi J, Yokoyama A . Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM), a metal complex with selective NADH-dependent reduction by complex I in brain mitochondria: a potential radiopharmaceutical for mitochondria-functional imaging with positron emission tomography (PET). Biol Pharm Bull 1995;18:1126–9.
Minkel DT, Saryan LA, Petering DH . Structure–function correlations in the reaction of bis(thiosemicarbazonato) copper(II) complexes with Ehrlich ascites tumor cells. Cancer Res 1978;38:124–9.
Wallhaus TR, Lacy J, Whang J, Green MA, Nickles RJ, Stone CK . Human biodistribution and dosimetry of the PET perfusion agent copper-62-PTSM. J Nucl Med 1998;39:1958–64.
Niciu MJ, Ma XM, El Meskini R, Ronnett GV, Mains RE, Eipper BA . Developmental changes in the expression of ATP7A during a critical period in postnatal neurodevelopment. Neuroscience 2006;139:947–64.
Yoshimura N . Histochemical localization of copper in various organs of brindled mice. Pathol Int 1994;44:14–9.
Kodama H, Meguro Y, Abe T,et al. Genetic expression of Menkes disease in cultured astrocytes of the macular mouse. J Inherit Metab Dis 1991;14:896–901.
Maehara M, Ogasawara N, Mizutani N, Watanabe K, Suzuki S . Cytochrome c oxidase deficiency in Menkes kinky hair disease. Brain Dev 1983;5:533–40.
Munakata M, Sakamoto O, Kitamura T,et al. The effects of copper-histidine therapy on brain metabolism in a patient with Menkes disease: a proton magnetic resonance spectroscopic study. Brain Dev 2005;27:297–300.
Wong-Riley MT . Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci 1989;12:94–101.
Taniuchi H, Fujibayashi Y, Yonekura Y, Konishi J, Yokoyama A . Hyperfixation of copper-62-PTSM in rat brain after transient global ischemia. J Nucl Med 1997;38:1130–4.
Wijburg FA, Feller N, Scholte HR, Przyrembel H, Wanders RJ . Studies on the formation of lactate and pyruvate from glucose in cultured skin fibroblasts: implications for detection of respiratory chain defects. Biochem Int 1989;19:563–70.
Petering HG, Buskirk HH, Underwood GE . The anti-tumor activity of 2-keto-3-ethoxybutyraldehyde bis(thiosemicarbazone) and related compounds. Cancer Res 1964;24:367–72.
Kostyniak PJ, Nakeeb SM, Schopp EM,et al. Acute toxicity and mutagenicity of the copper complex of pyruvaldehyde-bis (N-4-methylthiosemicarbazone), Cu-PTSM. J Appl Toxicol 1990;10:417–21.
Ozawa H, Kodama H, Kawaguchi H, Mochizuki T, Kobayashi M, Igarashi T . Renal function in patients with Menkes disease. Eur J Pediatr 2003;162:51–2.
Kodama H, Okabe I, Kihara A, Mori Y, Okaniwa M . Renal tubular function of patients with classical Menkes disease. J Inherit Metab Dis 1992;15:157–8.
David NA . The pharmacology of dimethyl sulfoxide. Annu Rev Pharmacol 1972;12:353–74.
Thomas R . Practical Guide to ICP-MS. New York, NY: Marcel Dekker, 2004; pp. 207–44.
Wong-Riley M . Changes in the visual system of monocularly sutured or enucleated cats demonstrable with cytochrome oxidase histochemistry. Brain Res 1979;171:11–28.
Strazielle C, Krémarik P, Ghersi-Egea JF, Lalonde R . Regional brain variations of cytochrome oxidase activity and motor coordination in Lurcher mutant mice. Exp Brain Res 1998;121:35–45.
Franklin KB, Paxinos G . The mouse brain in stereotaxic coordinates. San Diego, California: Academic Press, 1944.
Darriet D, Der T, Collins RC . Distribution of cytochrome oxidase in rat brain: studies with diaminobenzidine histochemistry in vitro and [14C]cyanide tissue labeling in vivo. J Cereb Blood Flow Metab 1986;6:8–14.
Gonzalez-Lima F, Jones D . Quantitative mapping of cytochrome oxidase activity in the central auditory system of the gerbil: a study with calibrated activity standards and metal-intensified histochemistry. Brain Res 1994;660:34–49.
Acknowledgements
We thank Yoshimasa Sakamoto, Makoto Miyagawa, Wataru Takimoto, Aoi Takemata, Yoko Chiba, Shinichiro Shimada, Mio Miyazawa, and Yayoi Takahashi for providing technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Munakata, M., Kodama, H., Fujisawa, C. et al. Copper-trafficking efficacy of copper-pyruvaldehyde bis(N4-methylthiosemicarbazone) on the macular mouse, an animal model of Menkes disease. Pediatr Res 72, 270–276 (2012). https://doi.org/10.1038/pr.2012.85
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/pr.2012.85
This article is cited by
-
Cuproptosis: mechanisms and links with cancers
Molecular Cancer (2023)
-
Pharmacokinetics of CuGTSM, a Novel Drug Candidate, in a Mouse Model of Menkes Disease
Pharmaceutical Research (2021)
-
Menkes disease: Oral administration of glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) rescues the macular mouse
Pediatric Research (2018)
